Objective: The paper compares the clinical efficacy and safety of levofloxacin and sodium chloride injection in the national centralized procurement with that of the original drug for the treatment of community-acquired pneumonia (CAP). Methods: Clinical information related to patients diagnosed with CAP and using levofloxacin and sodium chloride injection in a large tertiary hospital of Fujian Province from October 20, 2020 to October 20, 2022 was retrospectively collected, and the propensity score matching method was used to adjust the differences between the groups and to compare the efficacy and safety of the two groups. Results: After propensity score matching, 117 patients were included in the generic group and 117 patients were included in the original group. There was no statistically significant difference between the two groups in terms of clinical response rate, leukocytes, neutrophil percentage, C-reactive protein, calcitoninogen, body temperature, and the duration of drug administration (days) between the two groups on the seventh day of medication. There was no statistically significant difference in liver and kidney function abnormalities between the two groups after medication. Conclusion: The efficacy and safety of levofloxacin and sodium chloride injection national centralized procurement is equivalent to that of the original drug for the treatment of CAP.